Reading time: ~2 min · Part of the free certification in peptide science
The strength of this class rests on large clinical trial programs, whose names are worth recognizing:
- SUSTAIN and STEP — semaglutide in glycemic control and weight management, respectively.
- SURPASS and SURMOUNT — tirzepatide in glycemic control and weight.
- SELECT — semaglutide and cardiovascular outcomes.
| Compound | Receptors | Reported differentiating trait |
|---|---|---|
| Semaglutide | GLP-1 | Weekly reference; favorable cardiovascular signal |
| Tirzepatide | GIP + GLP-1 | Greater metabolic magnitude than GLP-1 alone |
| Retatrutide | GLP-1 + GIP + glucagon | Energy expenditure component; early-phase data |
| Cagrilintide | Amylin | Complementary satiety; synergy with GLP-1 |
The conceptual axis for the professional: more co-activated targets mobilize more metabolic levers, at the cost of more complex pharmacology. The most frequent events of the class are gastrointestinal (nausea, early satiety), consistent with gastric slowing and typically dependent on the titration speed — a point taken up again in the safety Module.
Catalogue compounds mentioned in this lesson
Take the module 3 quiz and earn your certificate
The certification is free: read the lessons, pass each module quiz and the final exam, and download your PDF certificate with a verifiable ID.
Go to the quiz →Educational content for scientific purposes. It distinguishes preclinical from clinical evidence and is not medical advice, diagnosis or a recommendation for use. NeoPeptidos products are sold labelled for research use only (RUO).